Non-Cash Revenue Related To The Sale Of Future Royalties was Agenus’s largest product and service line in fiscal 2025, bringing in $108.59M of $114.20M (95%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Non-Cash Revenue Related To The Sale Of Future Royalties | $114.57M | $100.98M | $108.59M | ||||||
| License Fees & Milestones | $25.00M | — | — | ||||||
| License Fee Revenue | — | — | — | ||||||
| Non-Cash Royalties | — | — | — | ||||||
| Non-Cash Royalty Revenue Related To The Sale Of Future Royalties & Milestones | — | — | — | ||||||
| Non Cash Royalty Revenue Related To The Sale Of Future Royalties & Milestone | — | — | — | ||||||
| License & Collaboration Milestones | — | — | — | ||||||
| Royalty Sales Milestone | — | — | — | ||||||
| Recognition Of Deferred Research & Development Revenue | $12.21M | — | — | ||||||
| Research & Development Services | $1.44M | — | — | ||||||
| Pre-Commercial Product Revenue | — | — | $4.24M | ||||||
| Recognition Of Deferred Revenue | — | — | — | ||||||
| Other Services | $2.98M | $2.00M | $1.04M | ||||||
| Manufacturing Services | — | — | — | ||||||
| Clinical Product Revenue | $116.00K | $482.00K | $334.00K | ||||||
| Recognition Of Deferred Grant Revenue | — | — | — | ||||||
| Grant Revenue | — | — | — | ||||||
| Other Revenue | — | — | — | ||||||
| Service Revenue | — | — | — | ||||||
| Total | $156.31M | $103.46M | $114.20M |
Agenus brought in $114.20M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. Agenus regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $103.46M. Non-Cash Revenue Related To The Sale Of Future Royalties was the largest at $108.59M (95.1%), ahead of Pre-Commercial Product Revenue at $4.24M (3.7%) and Other Services at $1.04M (0.9%). The remaining line, Clinical Product Revenue, brought in $334.00K.
Agenus began breaking out Pre-Commercial Product Revenue in fiscal 2025, when it brought in $4.24M. Agenus stopped reporting License Fees & Milestones ($25.00M in fiscal 2023), Recognition Of Deferred Research & Development Revenue ($12.21M in fiscal 2023) and Research & Development Services ($1.44M in fiscal 2023) as separate lines.
United States was Agenus’s largest region in fiscal 2025, bringing in $113.16M of $114.20M (99%).
| Geography | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $153.34M | $101.46M | $113.16M | ||||||||||
| Europe | — | — | — | ||||||||||
| Rest Of World | $2.98M | $2.00M | $1.04M | ||||||||||
| Total | $156.31M | $103.46M | $114.20M |
Agenus brought in $114.20M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 10.4% from $103.46M in fiscal 2024. United States was the largest at $113.16M (99.1%), ahead of Rest Of World at $1.04M (0.9%).
From fiscal 2023 to 2025, combined revenue from these regions fell from $156.31M to $114.20M, a compound annual decline of 14.5%. United States' share of the total rose from 98.1% to 99.1%.
Agenus (AGEN) reports its revenue by product and service and by geography. In fiscal 2025, Non-Cash Revenue Related To The Sale Of Future Royalties was its largest product and service line, bringing in $108.59M (95.1% of the total), followed by Pre-Commercial Product Revenue at $4.24M (3.7%).
Non-Cash Revenue Related To The Sale Of Future Royalties was Agenus' largest product and service line in fiscal 2025, bringing in $108.59M, or 95.1% of the $114.20M total across its four product and service lines.
United States was Agenus' largest region in fiscal 2025, bringing in $113.16M, or 99.1% of the $114.20M total across its two regions.
Every figure comes from Agenus' annual financial filings, as reported. Each line keeps the name Agenus gives it, and years follow its fiscal calendar.
Agenus' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.